TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2857117

Group type: COMPARATOR
Intervention: Nizatidine 6.25, 25, 75, 150, or 250 mg (single 20-min intravenous infusion)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nizatidine 25, 50, 100, or 250 mg (5-min intravenous infusion weekly for 6 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cimetidine 300 mg (5-min intravenous infusion weekly for 6 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (5-min intravenous infusion weekly for 6 weeks)
Number of subjects: 15
Study: 29410180

Group type: EXPERIMENTAL
Intervention: Plerixafor plus 10 µg/kg G-CSF
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo plus 10 µg/kg G-CSF
Number of subjects: 330
Study: 26773784

Group type: EXPERIMENTAL
Intervention: Almonds (1.5 oz for parents, 0.5 oz for children)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (no almonds)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Almonds
Number of subjects: 58
Study: 24523007

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)‐based counseling intervention called Uphungu Wanga
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief education sessions about HIV and AHI
Number of subjects: 0
Study: 21977812

Group type: EXPERIMENTAL
Intervention: Busui Shengxue Granule
Number of subjects: 65

Group type: COMPARATOR
Intervention: Zaizhang Shengxue Tablet
Number of subjects: 65
Study: 19214129

Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 484

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 484
Study: 16472855

Group type: EXPERIMENTAL
Intervention: In-office bleaching with 38% hydrogen peroxide for 15, 30, and 45 minutes
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (unbleached samples)
Number of subjects: 84
Study: 15791379

Group type: EXPERIMENTAL
Intervention: Fenyö-Lindberg scoring system
Number of subjects: 455
Study: 11309012

Group type: EXPERIMENTAL
Intervention: B‐IINB (ilioinguinal and iliohypogastric nerve block) with 10 ml of 0.5% bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: S‐IINB (saline control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (B‐IINB and S‐IINB)
Number of subjects: 100
Study: 9154850

Group type: EXPERIMENTAL
Intervention: Education and action plan based on peak-flow monitoring (Group P)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Education with action plan based on monitoring of asthma symptoms (Group S)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Education and action plan based on peak-flow monitoring (Group P) and Education with action plan based on monitoring of asthma symptoms (Group S)
Number of subjects: 188
Study: 8102665

Group type: EXPERIMENTAL
Intervention: Habitual sports and exercise activities (experimental group)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Advised not to play 'risky' sports (control group)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Children with normal atlantoaxial distances (third group)
Number of subjects: 400
Study: 3311954

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 117
Study: 359083

Group type: EXPERIMENTAL
Intervention: Oral neomycin and metronidazole added to bowel preparation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard mechanical preparation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 120
Study: 30099769

Group type: EXPERIMENTAL
Intervention: HaemoCer™ (absorbable polysaccharide hemostatic powder)
Number of subjects: 155
Study: 28557585

Group type: EXPERIMENTAL
Intervention: IMRT and concurrent 5-FU/MMC
Number of subjects: 26
Study: 25766094

Group type: EXPERIMENTAL
Intervention: Mechanical CPR
Number of subjects: 206

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 206
Study: 23357614

Group type: EXPERIMENTAL
Intervention: Integrated information display
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional displays
Number of subjects: 12
Study: 21412803

Group type: EXPERIMENTAL
Intervention: IAA PDT
Number of subjects: 14
Study: 19586142

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance intervention (TA) added to usual treatment
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: 2‐session, counseling and education, HIV/HCV risk reduction intervention (C&E) added to usual treatment
Number of subjects: 632

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 632
Study: 17542057

Group type: COMPARATOR
Intervention: Standard 30-min infusion of gemcitabine (1200 mg/m(2))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fixed dose rate (FDR) infusion of gemcitabine (10 mg/(m(2) x min))
Number of subjects: 12
Study: 15482353

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg tablets (early treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sumatriptan 100 mg tablets (late treatment)
Number of subjects: 0
Study: 11574356

Group type: EXPERIMENTAL
Intervention: Music during the perioperative period (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No music (Group II)
Number of subjects: 50
Study: 9691162

Group type: EXPERIMENTAL
Intervention: Reduction of glucose intake (n = 11)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Insulin infusion (n = 12)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 56
Study: 7892363

Group type: EXPERIMENTAL
Intervention: Physical activity (exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excessive exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Competitive athletics involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise pre-dating dieting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased physical activity levels
Number of subjects: 0
Study: 3360972

Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alprazolam (1 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam (2 mg IV)
Number of subjects: 0
Study: 29621098

Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulation (VRS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: High-Fidelity Mannequin (group M)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of procedure time
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of global rating scale scores
Number of subjects: 46
Study: 28103915

Group type: EXPERIMENTAL
Intervention: Community health volunteers (CHVs) providing health education, oral rehydration solutions, and zinc tablets for diarrhea, and diagnosing malaria.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving no intervention during the first phase.
Number of subjects: 0
Study: 26581144

Group type: EXPERIMENTAL
Intervention: VAC (vincristine, dactinomycin, cyclophosphamide) or VAC alternating with VTC (topotecan) for 42 weeks, with local therapy of 50.4 Gy radiation therapy with or without delayed primary excision starting at week 12 for group III patients.
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Local therapy with 36-41.4 Gy radiation therapy for group I/II alveolar RMS patients.
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Tumors ≥5 cm
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Retroperitoneal (RP) tumors
Number of subjects: 423
Study: 23219491

Group type: EXPERIMENTAL
Intervention: Positive CBM-I training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Neutral CBM-I training
Number of subjects: 28
Study: 21338720

Group type: EXPERIMENTAL
Intervention: Topical phenytoin dressing once daily
Number of subjects: 104

Group type: COMPARATOR
Intervention: Normal saline dressing
Number of subjects: 104
Study: 18451347

Group type: EXPERIMENTAL
Intervention: EPA group (n=8841)
Number of subjects: 18145

Group type: COMPARATOR
Intervention: no EPA group (n=8862)
Number of subjects: 18145

Group type: EXPERIMENTAL
Intervention: EPA group (n=485)
Number of subjects: 18145

Group type: COMPARATOR
Intervention: no EPA group (n=457)
Number of subjects: 18145
Study: 16750451

Group type: EXPERIMENTAL
Intervention: GAL-ER
Number of subjects: 965

Group type: COMPARATOR
Intervention: GAL-IR
Number of subjects: 965

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 965
Study: 15645861

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 7.5% sodium hexametaphosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 0
Study: 11336940

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unoprostone 0.12% twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of Latanoprost vs Unoprostone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 60
Study: 9217619

Group type: EXPERIMENTAL
Intervention: 10-minute office-staff administered screen for malnutrition/weight loss, visual impairment, hearing loss, cognitive impairment, urinary incontinence, depression, physical limitations, and reduced leg mobility.
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: 10-minute office-staff administered screen
Number of subjects: 261
Study: 8429694

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 60
Study: 3542916

Group type: COMPARATOR
Intervention: Standard schedule (5 fractions per week of 180 to 200 cGy per day, total dose of 6600‐7380 cGy)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Hyperfractionation regimen (two fractions of 120 cGy per day, total of 6000 cGy)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Standard schedule
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Hyperfractionation schedule
Number of subjects: 187
Study: 30517236

Group type: EXPERIMENTAL
Intervention: Blood pressure levels in schoolchildren
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Systolic and diastolic blood pressure analysis
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Growth measurements
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Prevalence of pre-hypertension and arterial hypertension
Number of subjects: 1082
Study: 26223834

Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted distal gastrectomy (LADG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 63
Study: 24715213

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) followed by D2 gastrectomy
Number of subjects: 69
Study: 23429740

Group type: EXPERIMENTAL
Intervention: NUCAI (nurse-led psychosocial intervention), consisting of six bimonthly 45-minute counseling sessions, aimed at managing physical, psychological, and social consequences of HNC and its treatment.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care (control group, n = 102)
Number of subjects: 205
Study: 20646356

Group type: EXPERIMENTAL
Intervention: Cranberry extract tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18814223

Group type: EXPERIMENTAL
Intervention: Intracoronary propranolol
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 16502132

Group type: EXPERIMENTAL
Intervention: PALS (Positive Attitudes toward Learning in School)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Referral to neighborhood mental health clinic
Number of subjects: 90
Study: 12740731

Group type: EXPERIMENTAL
Intervention: Polar S710 mobile cycling powermeter
Number of subjects: 52
Study: 10959510

Group type: EXPERIMENTAL
Intervention: Gore External Valve Support (EVS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment (ligation or stripping)
Number of subjects: 30
Study: 8793522

Group type: EXPERIMENTAL
Intervention: Zoladex (3 months before surgery)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 247
Study: 1464343

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 1 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 2 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 3 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study: 6369581

Group type: EXPERIMENTAL
Intervention: Preincisional cefamandole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous cefamandole
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotics (Control)
Number of subjects: 0
Study: 31882021

Group type: EXPERIMENTAL
Intervention: Increased consumption of refined grains (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of red meat (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of potatoes (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of alcoholic beverages (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of processed meat (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of white bread (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of sweets (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of low-fat yogurt (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of low-fat milk (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of snacks, fast-foods and pre-prepared dishes (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of vegetables (1 serving/d)
Number of subjects: 7009

Group type: EXPERIMENTAL
Intervention: Increased consumption of nuts (1 serving/d)
Number of subjects: 7009
Study: 28940962

Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 15 L/min
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 30 L/min
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 45 L/min
Number of subjects: 48

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 48
Study: 27221555

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPI) long-term therapy
Number of subjects: 0
Study: 24337877

Group type: EXPERIMENTAL
Intervention: Non-invasive hydrotransmissive electrical stimulation (15) of the ear
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo electrical stimulation
Number of subjects: 120
Study: 22317655

Group type: EXPERIMENTAL
Intervention: Exercise reminder software program (used for 10 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 20534752

Group type: EXPERIMENTAL
Intervention: Exercise (1-hour ergometer cycling at 65% maximal oxygen uptake)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fasting (72 hours)
Number of subjects: 8
Study: 17993008

Group type: EXPERIMENTAL
Intervention: Shenwu gelatin capsule (5 capsules, 3 times a day for 3 months)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Aniracetam (2 capsules) with 3 placebo capsules (3 times a day for 3 months)
Number of subjects: 166
Study: 16118755

Group type: EXPERIMENTAL
Intervention: Posterior mini-incision approach for THA
Number of subjects: 76
Study: 12106834

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 10413761

Group type: EXPERIMENTAL
Intervention: HCC (heparin-coated circuits)
Number of subjects: 60

Group type: COMPARATOR
Intervention: NHCC (uncoated circuits)
Number of subjects: 60
Study: 7675881

Group type: EXPERIMENTAL
Intervention: Complete caffeine deprivation (100% of daily caffeine intake)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Partial caffeine deprivation (50% of daily caffeine intake)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No caffeine deprivation (0% of daily caffeine intake)
Number of subjects: 9
Study: 2126794

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 24
Study: 6110953

Group type: EXPERIMENTAL
Intervention: CNS radiation prophylaxis
Number of subjects: 3161

Group type: COMPARATOR
Intervention: 3 years of maintenance treatment
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: 5 years of maintenance treatment
Number of subjects: 3161
Study: 31514107

Group type: EXPERIMENTAL
Intervention: Skeletal muscle radiomic features
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Prediction model for muscle loss using 193 features
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Differences in intensity and texture radiomic features over time
Number of subjects: 116
Study: 29872264

Group type: EXPERIMENTAL
Intervention: levodropropizine CR 90 mg two times in the fed state (TF)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: levodropropizine CR 90 mg two times in the fasted state (T)
Number of subjects: 47

Group type: COMPARATOR
Intervention: levodropropizine IR 60 mg three times in the fasted state (R)
Number of subjects: 47
Study: 26185283

Group type: EXPERIMENTAL
Intervention: Low-Glycemic Index (LGI) diet (n = 72; target GI ∼50)
Number of subjects: 139

Group type: COMPARATOR
Intervention: High-Fiber (HF) diet (n = 67; target GI ∼60)
Number of subjects: 139
Study: 25175696

Group type: EXPERIMENTAL
Intervention: NT-proBNP concentration change during admission
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: NT-proBNP concentration change from discharge to 1 month after discharge
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Absolute NT-proBNP concentration at 1 month after discharge
Number of subjects: 309
Study: 21818642

Group type: EXPERIMENTAL
Intervention: 0.5 g ginger
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 1.0 g ginger
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 1.5 g ginger
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study: 19336855

Group type: EXPERIMENTAL
Intervention: Regular intensifying screens
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Medium intensifying screens
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Digital radiography
Number of subjects: 45
Study: 17767803

Group type: EXPERIMENTAL
Intervention: Inert cellulose powder
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (lactose powder)
Number of subjects: 15
Study: 16946178

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study: 12103457

Group type: EXPERIMENTAL
Intervention: ECT without atropine
Number of subjects: 29

Group type: COMPARATOR
Intervention: ECT with atropine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cumulative poststimulus RPP
Number of subjects: 29
Study: 9527731

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study: 7892822

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 392

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 392
Study: 2649632

Group type: EXPERIMENTAL
Intervention: Propranolol at 80 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Atenolol at 50 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metoprolol at 100 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Renal clearance and urinary excretion
Number of subjects: 32
Study: 788891

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + methyl CCNU
Number of subjects: 146

Group type: COMPARATOR
Intervention: Methyl CCNU alone
Number of subjects: 146

Group type: COMPARATOR
Intervention: Methyl CCNU with cyclophosphamide induction
Number of subjects: 146

Group type: COMPARATOR
Intervention: 5‐FU + methyl CCNU with cyclophosphamide induction
Number of subjects: 146
Study: 31003666

Group type: EXPERIMENTAL
Intervention: Massage using sweet almond oil
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage using lavender and sweet almond oil
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 28760007

Group type: EXPERIMENTAL
Intervention: Double fortified salt (DFS)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Salt fortified with iodine (control)
Number of subjects: 245
Study: 26200405

Group type: EXPERIMENTAL
Intervention: levobupivacaine + tramadol 50 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: levobupivacaine + fentanyl 150 mcg
Number of subjects: 80

Group type: COMPARATOR
Intervention: levobupivacaine 2.5 mg/ml
Number of subjects: 80

Group type: COMPARATOR
Intervention: saline
Number of subjects: 80
Study: 22390703

Group type: EXPERIMENTAL
Intervention: Reward-informed condition
Number of subjects: 84

Group type: COMPARATOR
Intervention: Reward-uninformed condition
Number of subjects: 84
Study: 21680932

Group type: EXPERIMENTAL
Intervention: Community health worker intervention providing diabetes self-management education and regular home visits for 6 months
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (delayed control)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 164
Study: 19073386

Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flammazine (Control)
Number of subjects: 40
Study: 15946711

Group type: EXPERIMENTAL
Intervention: Right-side vertically arranged stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipsilesional 'good' side stimuli
Number of subjects: 0
Study: 14514648

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1168
Study: 11451211

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 0
Study: 9625405

Group type: EXPERIMENTAL
Intervention: Diet plus partial ileal bypass intervention
Number of subjects: 838

Group type: COMPARATOR
Intervention: Diet control
Number of subjects: 838
Study: 7749401

Group type: EXPERIMENTAL
Intervention: Smoking (dental history variable)
Number of subjects: 310